Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Japan Lifeline Co., Ltd. (7575.T)
Tokyo, JP
Japan Lifeline Co., Ltd. is a medical technology firm based in Japan that specializes in cardiovascular healthcare devices. Its operations encompass research, manufacturing, global procurement, and sales of these specialized medical instruments within the country. The company's diverse product range includes solutions for cardiac rhythm management, such as pacemakers, implantable cardioverter defibrillators (including subcutaneous models), cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support tools. For electrophysiology and ablation procedures, Japan Lifeline offers various electrophysiological and ablation catheters (like irrigated tip versions), endoscopic balloon ablation systems, esophageal temperature monitors, internal atrial cardioversion systems, and radio-frequency transseptal needles. Furthermore, its portfolio extends to cardiovascular and endografting products, including vascular, open, and abdominal stent-grafts. In the transvascular intervention segment, the company provides PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and devices for closing atrial septal defects. Complementing these, its gastrointestinal intervention solutions encompass radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Established in 1981, Japan Lifeline Co., Ltd. maintains its headquarters in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.26% | -0.47% | -12.40% | -9.17% | -13.95% | -22.20% | -11.47% | +15.94% | -10.84% | +50.43% | +465.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+4.6% Q1'26: +7.1% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+1.4% Q1'26: +12.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+11.5% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+21.3% ★ Q1'26: +14.1% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+16.8% ★ Q1'26: +12.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-1.0% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.21× ★ Q1'26: 0.27× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 3 Rev. Ana. 3 EPS Ana. |
Mar 2027 3 Rev. Ana. 2 EPS Ana. |
Mar 2028 3 Rev. Ana. 3 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
37.18B
est: 37.30B (-0.3%)
|
42.30B
est: 42.46B (-0.4%)
|
45.53B
est: 45.58B (-0.1%)
|
51.76B
est: 52.26B (-1.0%)
|
51.29B
est: 51.69B (-0.8%)
|
51.47B
est: 52.56B (-2.1%)
|
51.75B
est: 51.31B (+0.9%)
|
51.38B
est: 52.44B (-2.0%)
|
56.61B
est: 56.92B (-0.5%)
|
59.00B
58.92B – 59.08B
+3.6% YoY
|
61.34B
60.54B – 62.00B
+4.0% YoY
|
64.61B
62.92B – 67.00B
+5.3% YoY
|
67.46B
66.13B – 69.10B
+4.4% YoY
|
71.54B
70.13B – 73.27B
+6.0% YoY
|
| EBITDA |
8.65B
est: 8.05B (+7.4%)
|
11.77B
est: 9.17B (+28.3%)
|
11.79B
est: 9.84B (+19.8%)
|
11.90B
est: 11.28B (+5.4%)
|
11.68B
est: 11.16B (+4.7%)
|
11.89B
est: 11.35B (+4.8%)
|
12.72B
est: 11.08B (+14.8%)
|
12.83B
est: 12.91B (-0.6%)
|
14.62B
est: 14.01B (+4.3%)
|
14.52B
14.50B – 14.54B
+3.6% YoY
|
15.10B
14.90B – 15.26B
+4.0% YoY
|
15.90B
15.49B – 16.49B
+5.3% YoY
|
16.60B
16.28B – 17.01B
+4.4% YoY
|
17.61B
17.26B – 18.03B
+6.0% YoY
|
| EBIT |
7.69B
est: 6.70B (+14.7%)
|
10.67B
est: 7.63B (+39.9%)
|
10.53B
est: 8.18B (+28.6%)
|
10.44B
est: 9.38B (+11.2%)
|
9.84B
est: 9.28B (+6.0%)
|
9.96B
est: 9.44B (+5.5%)
|
10.84B
est: 9.21B (+17.6%)
|
11.04B
est: 11.03B (+0.1%)
|
12.52B
est: 11.97B (+4.6%)
|
12.41B
12.39B – 12.42B
+3.6% YoY
|
12.90B
12.73B – 13.04B
+4.0% YoY
|
13.59B
13.23B – 14.09B
+5.3% YoY
|
14.19B
13.91B – 14.53B
+4.4% YoY
|
15.05B
14.75B – 15.41B
+6.0% YoY
|
| Net Income |
5.35B
est: 4.44B (+20.6%)
|
7.48B
est: 6.74B (+11.0%)
|
7.72B
est: 6.38B (+21.1%)
|
7.75B
est: 6.82B (+13.5%)
|
2.00B
est: 2.73B (-26.7%)
|
7.48B
est: 6.60B (+13.4%)
|
6.89B
est: 6.76B (+1.9%)
|
7.52B
est: 7.06B (+6.5%)
|
9.32B
est: 8.90B (+4.7%)
|
8.85B
8.61B – 9.10B
-0.5% YoY
|
9.37B
9.26B – 9.48B
+5.8% YoY
|
10.28B
9.36B – 11.00B
+9.7% YoY
|
10.80B
9.63B – 12.10B
+5.1% YoY
|
11.60B
11.30B – 11.97B
+7.5% YoY
|
| SGA |
12.83B
est: 7.43B (+72.6%)
|
14.37B
est: 8.46B (+69.9%)
|
15.33B
est: 9.08B (+68.8%)
|
16.54B
est: 10.41B (+58.9%)
|
16.07B
est: 10.30B (+56.1%)
|
15.74B
est: 10.47B (+50.3%)
|
15.83B
est: 10.22B (+54.9%)
|
16.97B
est: 16.50B (+2.9%)
|
17.73B
est: 17.90B (-1.0%)
|
18.56B
18.53B – 18.58B
+3.6% YoY
|
19.29B
19.04B – 19.50B
+4.0% YoY
|
20.32B
19.79B – 21.08B
+5.3% YoY
|
21.22B
20.80B – 21.74B
+4.4% YoY
|
22.50B
22.06B – 23.05B
+6.0% YoY
|
| EPS |
71.90
est: 62.60 (+14.9%)
|
98.51
est: 95.05 (+3.6%)
|
96.04
est: 89.98 (+6.7%)
|
96.55
est: 96.27 (+0.3%)
|
24.90
est: 38.48 (-35.3%)
|
93.12
est: 93.09 (+0.0%)
|
88.22
est: 95.40 (-7.5%)
|
98.72
est: 100.28 (-1.6%)
|
131.43
est: 126.47 (+3.9%)
|
125.53
122.67 – 129.71
-0.7% YoY
|
133.57
132.00 – 135.13
+6.4% YoY
|
143.43
133.40 – 156.80
+7.4% YoY
|
154.90
137.30 – 172.50
+8.0% YoY
|
165.35
161.12 – 170.57
+6.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.08% | 317.7K | 0.58% |
| 2 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.06% | 667.0K | 0.40% |
| 3 | iShares Ageing Population UCITS ETF AGED.L | 0.04% | 375.6K | 0.40% |
| 4 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.03% | 195.4K | 0.58% |
| 5 | State Street SPDR S&P International Small Cap ETF GWX | 0.03% | 278.8K | 0.40% |
| 6 | iShares MSCI Japan Small-Cap ETF SCJ | 0.03% | 81.2K | 0.50% |
| 7 | WisdomTree International SmallCap Dividend Fund DLS | 0.03% | 278.4K | 0.58% |
| 8 | Schwab International Small-Cap Equity ETF SCHC | 0.02% | 886.8K | 0.06% |
| 9 | Avantis Responsible International Equity ETF AVSD | 0.02% | 76.9K | 0.23% |
| 10 | Avantis International Small Cap Equity ETF AVDS | 0.02% | 48.1K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Keisuke Suzuki | President, Chief Executive Officer & Representative Director | — | male |
| Kenji Yamada | Director, Executive Officer & Head of Corporate Administration Group | — | male |
| KuNobuo Takahashi | Senior Operating Officer & Head of Global Business Development Group | — | — |
| Naohiro Nakada | Senior Operating Officer & Deputy Head of Arrhythmia Business Operations Group | — | — |
| Takashi Ito | Executive Officer, Head of Arrhythmia Business Operations Group & Director | — | male |
| Takeyoshi Egawa | Director, Executive Officer & Head of Corporate Management Group | — | male |
| Tatsuya Murase | Vice President, Chief Operating Officer & Representative Director | — | male |
| Toru Takamiya | Senior Executive Officer, Head of R&D and Production Group & Director | — | male |
| Toshihiro Miyake | Executive Officer and General Manager of RA Division R & D & Production Group | — | — |
| Yoshiaki Ikei | Independent Outside Director | — | male |
| Yumiko Hoshiba | Director, Senior Operating Officer & GM of Operations Division of Corporate Administration Group | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7575.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
